Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for
treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we …

Circulating adiponectin concentrations are reduced in obese individuals, and this reduction
has been proposed to have a crucial role in the pathogenesis of atherosclerosis and …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Context Obesity is responsible for an increased risk of sub-fecundity and infertility. Obese
women show poorer reproductive outcomes regardless of the mode of conception, and …

Polycystic ovary syndrome (PCOS) has multiple etiologies including ovarian and adrenal
hyperandrogenism, neuro-endocrine and hypothalamic-pituitary dysfunction, and disorders …

Context The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is reaching
epidemic proportions in the United States. This calls for greater awareness among …

Inflammation contributes to many chronic conditions. It is often associated with circulating
pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity …

Leptin, an adipokine that is implicated in the control of food intake via appetite suppression,
may also stimulate oxidative stress, inflammation, thrombosis, arterial stiffness …